(June 12, 2020, 1:08 PM EDT) -- NEW YORK — A microcap company misrepresented to investors that it had shifted its business from production of cannabinoid-based products to products used to battle the novel coronavirus, including a home test kit, and that it had “begun shipping” its line of home test kits to consumers in violation of federal securities law, the Securities and Exchange Commission argues in a May 14 complaint filed in New York federal court (Securities and Exchange Commission v. Applied Biosciences Corp., No. 20-3729, S.D. N.Y.)....